BPW
REGN icon

Bingham Private Wealth’s Regeneron Pharmaceuticals REGN Stock Holding History

Bingham Private Wealth’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$284K Buy
456
+2
+0.4% +$1.36K 0.2% 135
2026
Q1 		$351K Buy
454
+37
+9% +$28.3K 0.28% 108
2025
Q4 		$322K Buy
+417
New +$283K 0.28% 106
2025
Q2 		$224K Buy
+427
New +$238K 0.21% 140

Other funds holding REGN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Bingham Private Wealth's REGN Position: Q2 2026 in Review

Bingham Private Wealth increased its Regeneron Pharmaceuticals (REGN) stake by 0.44% in Q2 2026, buying an estimated $1.36K and bringing the position to 456 shares worth $284K. The position accounts for 0.2% of the portfolio, ranked #135.

Bingham Private Wealth first reported a position in REGN in Q2 2025 and has held it in 4 quarters since. The position peaked at $351K in Q1 2026. 1,335 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

  • Bingham Private Wealth held 456 shares of Regeneron Pharmaceuticals worth $284K as of Q2 2026.
  • Bingham Private Wealth bought 2 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $1.36K.
  • Regeneron Pharmaceuticals made up 0.2% of Bingham Private Wealth's portfolio in Q2 2026, its #135 holding.
  • Bingham Private Wealth first reported a position in Regeneron Pharmaceuticals in Q2 2025 and has held it in 4 quarters since.
  • Bingham Private Wealth's Regeneron Pharmaceuticals position peaked at $351K in Q1 2026.
  • 1,335 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on Bingham Private Wealth's 13F filing for Q2 2026, filed 11 Aug 2026.